HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ and K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases. London: England, 2020, vol. 15, No 1, p. 1-4. ISSN 1750-1172. Available from: https://dx.doi.org/10.1186/s13023-020-01511-8. |
Other formats:
BibTeX
LaTeX
RIS
@article{1681836, author = {Hermans, C. and Giangrande, P. L. F. and O Mahony, B. and de Kleijn, P. and Bedford, M. and Batorova, A. and Blatný, Jan and Jansone, K.}, article_location = {London}, article_number = {1}, doi = {http://dx.doi.org/10.1186/s13023-020-01511-8}, keywords = {Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance}, language = {eng}, issn = {1750-1172}, journal = {Orphanet Journal of Rare Diseases}, title = {European principles of inhibitor management in patients with haemophilia: implications of new treatment options}, url = {https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8}, volume = {15}, year = {2020} }
TY - JOUR ID - 1681836 AU - Hermans, C. - Giangrande, P. L. F. - O Mahony, B. - de Kleijn, P. - Bedford, M. - Batorova, A. - Blatný, Jan - Jansone, K. PY - 2020 TI - European principles of inhibitor management in patients with haemophilia: implications of new treatment options JF - Orphanet Journal of Rare Diseases VL - 15 IS - 1 SP - 1-4 EP - 1-4 PB - England SN - 17501172 KW - Haemophilia KW - Guidelines KW - Inhibitors KW - Factor VIII KW - Factor IX KW - Bypassing agents KW - Emicizumab KW - Immune tolerance UR - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8 L2 - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8 N2 - In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors). ER -
HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ and K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. \textit{Orphanet Journal of Rare Diseases}. London: England, 2020, vol.~15, No~1, p.~1-4. ISSN~1750-1172. Available from: https://dx.doi.org/10.1186/s13023-020-01511-8.
|